Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Kadmon to co-promote Valeant's Syprine in the US

Executive Summary

Valeant Pharmaceuticals International Inc. licensed Kadmon Corp. LLC (developing therapies for cancer, infectious diseases, immune disorders, and neurodegenerative diseases) US co-promotion rights to the Wilson's disease drug Syprine (trientine).
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Marketing-Licensing
    • Co-Promotion

Related Companies